Maxi Meissner

State of the Art: Newer Biomarkers in Heart Failure

Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure

Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease

Clinical Trials and Applications of Galectin Antagonists

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Bile acid–microbiota crosstalk in gastrointestinal inflammation and carcinogenesis

Markers of fibrosis, inflammation, and remodeling pathways in heart failure

Microbiota Modification with Probiotics Induces Hepatic Bile Acid Synthesis via Downregulation of the Fxr-Fgf15 Axis in Mice

Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile

The Emerging Role of Galectin-3 and ST2 in Heart Failure: Practical Considerations and Pitfalls Using Novel Biomarkers

Bile acid sequestrants

Cardiovascular effects of gliptins

Beyond intestinal soap—bile acids in metabolic control

Gut microbiome and health: mechanistic insights

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Idiopathic pulmonary fibrosis

Hepatic glucose sensing is required to preserve β cell glucose competence

The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Do Dipeptidyl Peptidase IV (DPP-IV) Inhibitors Cause Heart Failure?

Fructose as a key player in the development of fatty liver disease

Intestinal Crosstalk between Bile Acids and Microbiota and Its Impact on Host Metabolism

Type 2 diabetes mellitus

Energy Metabolism in the Liver

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

The pros, cons, and many unknowns of probiotics

Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure

Citrus polymethoxyflavones attenuate metabolic syndrome by regulating gut microbiome and amino acid metabolism

Resveratrol Attenuates Trimethylamine- N -Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota

Cardiovascular Biology of the Incretin System

2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America

A Role of the Bile Salt Receptor FXR in Atherosclerosis

Diabetic Cardiomyopathy

Dietary and Policy Priorities for Cardiovascular Disease, Diabetes, and Obesity

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

2016 ESC/EAS Guidelines for the Management of Dyslipidaemias

Cardiovascular Actions of Incretin-Based Therapies

Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review*

Bile Salt Sequestration Induces Hepatic De Novo Lipogenesis Through Farnesoid X Receptor– and Liver X Receptorα–Controlled Metabolic Pathways in Mice

Bile Acid Sequestration Reduces Plasma Glucose Levels in db/db Mice by Increasing Its Metabolic Clearance Rate

Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure

Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering With Myocardial Fibrogenesis